跳至主要内容
临床试验/NCT01744301
NCT01744301已完成不适用

A Cohort Study With a Nested Case Control Analysis on the Association Between Acid-suppressing Drugs and Seizures Using THIN Database in the UK

AstraZeneca1 个研究点 分布在 1 个国家目标入组 8,605 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
8,605
试验地点
1
主要终点
Incidence of seizure in the general population and stratified by epilepsy status.

研究概览

简要总结

The purpose of this study is

  1. to estimate the incidence of seizure in the general population and stratified by epilepsy status
  2. To estimate the relative risk of seizure associated with use of proton pump inhibitors and histamine 2 receptor antagonist and stratified by epilepsy status

详细描述

A cohort study with a nested case control analysis on the association between acid-suppressing drugs and seizures using THIN database in the UK

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Primary care physician for at least 2 years.
  • Computerized prescription history of at least 1 year.
  • Patients will have to be free of acid-suppressing drugs (PPI or H2RA) for at least one year.
  • No diagnosis of cancer.
  • No alcohol abuse or alcohol-related disease- No drug abuse.

排除标准

  • Patients with at least 1 prescription of PPI or H2RA in the year prior to start date.
  • Cancer before start date.
  • Alcohol abuse or alcohol-related disease before start date.
  • Drug abuse before start date.

研究组 & 干预措施

All patients newly prescribed PPI

All patients newly prescribed PPI

干预措施: Risk of seizure (Drug)

All patients newly prescribed H2RA

All patients newly prescribed H2RA

干预措施: Risk of seizure (Drug)

结局指标

主要结局

Incidence of seizure in the general population and stratified by epilepsy status.

时间窗: Participants will be followed for the duration of the study period 1 January 2005-31 December 2011, an expected average of 3 years.

Follow-up of safety outcomes: First recorded entry of seizure.

时间窗: Participants will be followed for the duration of the study period 1 January 2005-31 December 2011, an expected average of 3 years.

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验